Scholarlink

<p>Promethium-149 (<sup>149</sup>Pm) is a no carrier added radiolanthanide that emits moderate-energy beta particles and has high potential as a novel theranostic radioisotope for nuclear medicine applications. This study describes the production of the <sup>149</sup>Pm radioisotope from enriched neodymium oxide (Nd<sub>2</sub>O<sub>3</sub>) targets at the Bandung TRIGA research reactor and its supporting facilities, including theoretical calculations using computer codes, target preparation, neutron activation, separation of <sup>149</sup>Pm radionuclide from Nd/Pm matrix, purification, and physicochemical characterization. The obtained <sup>149</sup>Pm was in the form of a <sup>149</sup>PmCl<sub>3</sub> solution, which remained stable at room temperature for up to 8&#xa0;days after preparation with high radiochemical and radionuclide purities, thereby fulfilling the requirements for use as a precursor in the preparation of various targeted radiopharmaceuticals for cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Promethium-149 (149Pm) as a potential theranostic radioisotope: a feasibility study of 149Pm production at the Bandung TRIGA research reactor

  • 期刊论文

  • 发表日期：

    2026年4月16日

查看全文
  • Azmairit Aziz,
  • Efrizon Umar,
  • Prasetyo Basuki,
  • Neni Ratnawati,
  • Almira Fathadina,
  • Sidik Permana,
  • Anwar Ilmar Ramadhan

摘要

Promethium-149 (149Pm) is a no carrier added radiolanthanide that emits moderate-energy beta particles and has high potential as a novel theranostic radioisotope for nuclear medicine applications. This study describes the production of the 149Pm radioisotope from enriched neodymium oxide (Nd2O3) targets at the Bandung TRIGA research reactor and its supporting facilities, including theoretical calculations using computer codes, target preparation, neutron activation, separation of 149Pm radionuclide from Nd/Pm matrix, purification, and physicochemical characterization. The obtained 149Pm was in the form of a 149PmCl3 solution, which remained stable at room temperature for up to 8 days after preparation with high radiochemical and radionuclide purities, thereby fulfilling the requirements for use as a precursor in the preparation of various targeted radiopharmaceuticals for cancer therapy.